Kit qChip CM

The qChip® CM kit is a complete solution for conducting, in your own laboratory, comparative genomic hybridization experiments on oligonucleotide arrays, designed for the analysis of genetic alterations that cause more than two hundred developmental disorders, applicable both in both prenatal and postnatal stage.

We put all our experience at your disposal:

qChip® CM + qGenViewer

The optimal solution to implement microarray technology in hospital services.

Technical details

The qChip® CM (ref.13 / 3014), manufactured by Agilent, is specifically designed, developed and tested by qGenomics for the detection of small genetic copy number variants associated with developmental disorders:
• global coverage and higher resolution in candidate genes, in pericentromeric, subtelomeric regions associated with recurrent genomic syndromes
• +250 syndromes in a single test
• in accordance with ISCA recommendations and continuously updated
• tested on +2,000 samples
• continuously obtaining, since its first edition, maximum score in the external quality schemes of the EMQN

One microarray, multiple applications

Includes the reagents and the microarray needed for the analysis of up to 8 samples in a single experiment. The possibility of combining postnatal and prenatal samples makes it ideal for any cytogenetic laboratory and makes it a cost-efficient solution for all cases.

Developmental disorders affect between 1% and 3% of the population, and are characterized by the delay in the acquisition of motor, language, cognitive and / or social abilities of the child. This delay, which may or may not be associated with congenital malformations, has a genetic origin in a significant number of cases.

For the study of the genetic causes of this type of disorders at the pediatric stage, the international scientific and medical community agrees that the first test to be performed on a patient with idiopathic developmental delay, with or without malformations, is a genome study using a microarray, being the technology that offers a higher detection rate of genetic alterations (Miller et al., 2010). In the prenatal stage, it has also shown a higher rate of diagnosis of alterations causing pathology compared to the current gold standard of care (Sahoo et al 2006, Armengol et al 2011, Shaffer et al 2012, Srebniak et al 2013).

Despite the inconvenience for the genetic counseling of the detection of variants of copy number of uncertain significance (VOUS), the American society of gynecology and obstetrics (ACOG) recommends the use of microarrays in this area (ACOG Guidelines, Dec. 2013 ), given the scientific evidence of a higher rate of detection of genetic alterations that cause phenotype in prenatal diagnosis routines.